retatrutide triple agonist weight loss trial New Phase 3 data just dropped 👀 Eli Lilly's reported average approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Retatrutide for Obesity: Phase 2

Store your medication properly and note the injection site in your rotation log

Just make sure your medication is properly stored, as compounded formulations may have different stability profiles

We highlight how multireceptor agonists and oral GLP-1based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options

many remain on a stable maintenance dose after reaching their target

Clinical trials have reported that Retatrutide is generally well-tolerated, with most adverse events being mild to moderate in severity

That also means the product hasn't gone through the FDA drug approval process - supplements in this category are typically regulated under DSHEA, which requires safety but doesn't require pre-market proof of efficacy for specific medical conditions